Rep. Barton asks FDA if internal probe of data release to Summit precludes criminal prosecution.
This article was originally published in The Gray Sheet
Executive Summary
REP. BARTON DETERMINING IF "POSSIBLE CRIMINAL PROSECUTION" FOR FDA DATA RELEASE to Summit Technology has been "jeopardized" by FDA's in-house investigation of the agency's late-November breach of confidentiality. In a May 22 letter to FDA Commissioner David Kessler, Rep. Joe Barton (R-Tex.), chairman of the House Commerce/Oversight Subcommittee, states that "the subcommittee needs to be assured that the conduct of FDA's internal investigation has not jeopardized a possible referral or possible criminal prosecution."
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.